Solid Q2e on the cards
While the delay of Ovzon-3 and the situation with its previous partner have been headaches, we argue that Ovzon has taken several steps forward in recent years, including a broadened customer base and increased revenues (after the trough in 2021). On the back of recent order announcements, we expect Q2e to present sequential progress, where we see sales of SEK 87m (vs. SEK 57m in Q1).
Implied valuation
Following the upcoming launch of Ovzon-3, we expect sales to ramp up in the coming years. On our new estimates, the share is trading at 5x '25e EV/EBIT.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
